Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

1.910 +0.100 (+5.52%)
Streaming Delayed Price Updated: 2:05 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioXcel Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Why Shares of BioXcel Therapeutics Are Dropping Thursday
A trial for one of the company's therapies didn't meet its primary endpoint. 
Via The Motley Fool
BioXcel Stock Crashes 22% As Bid To Double Its Market Appears Less Certain
The company is hoping to double its market opportunity. But that looks less certain. 
Via Investor's Business Daily
Looking Into BioXcel Therapeutics's Return On Capital Employed
Via Benzinga
BioXcel Therapeutics Reports Encouraging Phase 1b Results For Innovative Depression Treatment
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced topline data from its Phase 1b multiple ascending dose (MAD) trial of BXCL501 (dexmedetomidine) sublingual film, for agitation associated with... 
Via Benzinga
Why These 3 Nasdaq Stocks Were Glowing Green This Week
These three biopharmaceutical stocks rocketed higher this week. 
Via The Motley Fool
The Latest Analyst Ratings for BioXcel Therapeutics
Via Benzinga
Why BioXcel Therapeutics Stock Marched Higher Today
The biotech's Q1 earnings report set the stage for a flurry of important clinical updates in the coming months. 
Via The Motley Fool
BioXcel Therapeutics's Earnings Outlook
Via Benzinga
6 Analysts Have This to Say About BioXcel Therapeutics
Via Benzinga
Earnings Preview: BioXcel Therapeutics
Via Benzinga
Expert Ratings for BioXcel Therapeutics
Via Benzinga
BioXcel Earnings Miss Q1 Estimates Due To Higher Costs, Expects Uptick In Revenues
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) reported first-quarter FY23 revenues of $206,000,  
Via Benzinga
Axsome Surges As Its Newest Product Shines. But BioXcel Does The Opposite.
Axsome shares are nearing a breakout point. But BioXcel crumbled on its report. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
The Next Evolution In Drugs? It's Artificial Intelligence, Says This CEO
This company is hoping to execute for a second time on its moonshot goal. 
Via Investor's Business Daily
Meta Platforms To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Tuesday
Morgan Stanley boosted the price target for HubSpot, Inc. (NYSE: HUBS) from $447 to $466. Morgan Stanley analyst Keith Weiss maintained an Overweight rating. HubSpot shares fell 1.9% to close at... 
Via Benzinga
Why BioXCel Therapeutics Stock Jumped This Week
A couple of analysts recently upgraded their views on the biotech stock. 
Via The Motley Fool
Analyst Ratings for BioXcel Therapeutics
Via Benzinga
Is This Soaring Growth Stock a Buy?
The answer may depend on your risk tolerance. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023
Via Benzinga
BioXcel Therapeutics Unveils Complete Data From BXCL701/Keytruda Combo Study In Prostate Cancer Subtype
Via Benzinga
Analyst Reiterates This Alzheimer's Candidate As Top Idea For 2023
Via Benzinga
ChatGPT Is Just The 'Tip Of The Iceberg' In Content-Creating Artificial Intelligence; Get Ready For 'A Lot Of Disruption' (Not Just At Google)
"A lot of disruption" may be coming soon to a host of industries. Google may be at risk. 
Via Investor's Business Daily
Recap: BioXcel Therapeutics Q2 Earnings
  BioXcel Therapeutics (NASDAQ:BTAI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
2 Beaten-Down Stocks to Watch Closely Next Year
These biotechs could skyrocket in 2023, but only if they can execute their plans. 
Via The Motley Fool
Why BioXcel Therapeutics Stock Triumphed This Week
An analyst feels that the best is shortly to come for the company. 
Via The Motley Fool
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BioXcel Therapeutics Inc (NASDAQ: BTAI) "may be home run or nothing, and that’s always tough." 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Gainers 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.